EXPLORE!

Novavax COVID vaccine over 90% effective in trial

  669 Views

eMediNexus    15 June 2021

Novavax Inc has released late-stage data from its U.S.-based clinical trial which suggests that its vaccine is over 90% effective against COVID-19 across different variants of the virus.

The trial included around 30,000 volunteers in the United States and Mexico. The company’s protein-based vaccine candidate was found to be over 93% effective against the predominant variants of the novel coronavirus. During the study, B.1.1.7 variant (first identified in the United Kingdom) became the predominant variant in the United States, stated the company. It also detected the variants first found in Brazil, South Africa and India among the trial participants, mentioned the company’s head of research and development, Dr. Gregory Glenn… (ET Healthworld – Reuters, June 14, 2021)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.